Pharsight

Zioptan patents expiration

ZIOPTAN's oppositions filed in EPO
ZIOPTAN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5886035 AKORN Difluoroprostaglandin derivatives and their use
Dec, 2022

(1 year, 3 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10864159 AKORN Method and composition for treating ocular hypertension and glaucoma
May, 2029

(5 years from now)

US9999593 AKORN Method and composition for treating ocular hypertension and glaucoma
May, 2029

(5 years from now)

Zioptan is owned by Akorn.

Zioptan contains Tafluprost.

Zioptan has a total of 3 drug patents out of which 1 drug patent has expired.

Expired drug patents of Zioptan are:

  • US5886035

Zioptan was authorised for market use on 10 February, 2012.

Zioptan is available in solution/drops;ophthalmic dosage forms.

Zioptan can be used as reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

The generics of Zioptan are possible to be released after 28 May, 2029.

Drugs and Companies using TAFLUPROST ingredient

Market Authorisation Date: 10 February, 2012

Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ZIOPTAN before it's drug patent expiration?
More Information on Dosage

ZIOPTAN family patents

Family Patents